Eugene

[email protected]

LATEST

Discovery Labs to Develop $500-Million Innovation Hub at Former GSK Site
By

By
The Discovery Labs, a platform company that develops co-working laboratory and office space for healthcare, life sciences and technology-enabled companies, has announced it is redeveloping a pair of sites in…

Thermo Fisher, Cambrex Expand; Lonza Carves Out Specialty Ingredients Segment
By

By
The latest news from CDMOs, CMOs, and suppliers featuring news from Thermo Fisher, Cambrex, Lonza, Vetter, Sterling Pharma, Fujifilm, PCI Pharma Services, Particle Sciences, Vibologics, iBio, and Parexel. Chemicals/Chemical API…

Zydus Cadila and Lupin Cited for Mfg Issues by FDA
By

By
Zydus Cadila, an Ahmedabad, India-based pharmaceutical company, reports that the US Food and Drug Administration (FDA) has issued 11 observations following an inspection of the company’s manufacturing facilities in St.…

FDA Seeking Public Input On Requirements For Blister Packaging Of Opioids
By

By
The US Food and Drug Administration (FDA) is opening a public docket to gain public input on the potential of requiring certain immediate-release opioid analgesics be made available in fixed-quantity,…

Iovance To Invest $75 Million in New Cell-Therapy Mfg Facility
By

By
Iovance Biotherapeutics, a late-stage biotechnology company specializing in immunotherapies for cancer, has entered into a lease agreement to build a 136,000 square-foot cell-therapy production facility in Philadelphia, Pennsylvania for commercial…

BI, Gubra In $269-Million Deal For Anti-Obesity Peptides
By

By
Boehringer Ingelheim (BI) and Gubra, a provider of contract services for drug discovery and development, have entered into a collaboration and license agreement for the development of poly-agonist peptides to…

CDMO Aldevron To Build New Gene and Cell Therapy Mfg. Campus
By

By
Aldevron, a contract provider specializing in the production of nucleic acids, proteins, and antibodies, has announced expansion plans for a new 14-acre campus for gene and cell therapy manufacturing at…

Mallinckrodt Updates Separation Plans and Specialty Generics Spin-Off
By

By
Mallinckrodt, a specialty pharmaceutical company, has updated its plans to create two independent, publicly traded companies: one focused on innovative specialty branded pharmaceuticals and the other concentrated primarily in specialty…

FDA Approves Novartis’ Gene Therapy Zolgensma and Breast-Cancer Drug Piqray
By

By
AveXis, a Novartis company, has received approval from the US Food and Drug Administration (FDA) for Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy for pediatric patients with spinal muscular atrophy…

Lilly, Centrexion In $622.5-Million Deal for Non-Opioid Drug
By

By
Eli Lilly and Company has entered into a licensing agreement with Centrexion Therapeutics, a late-clinical stage biopharmaceutical company, to acquire the exclusive global rights for CNTX-0290, a potential non-opioid treatment…